Home » Micro Therapeutics Receives $3.7 Million Payment
Micro Therapeutics Receives $3.7 Million Payment
Micro Therapeutics (MTI) has received a $3.7 million payment resulting from the acquisition of certain assets of Genyx Medical, a company in which MTI held a minority equity interest, by C. R. Bard. Genyx, a privately held company based in Aliso Viejo, Calif., licensed MTI's proprietary liquid embolic technology for certain non-vascular applications in 1997. Genyx recently announced that it had received FDA approval for URYX, an injectable tissue bulking agent for the treatment of stress urinary incontinence that is based on the technology licensed from MTI.
PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/02-01-2005/0002941366&EDATE=)
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May